IRUS Total

Circulating microRNAs in small-bowel neuroendocrine tumors: a potential tool for diagnosis and assessment of effectiveness of surgical resection

File Description SizeFormat 
Accepted Manuscript_Serum miRNAs in SBNET_PAPER_R1 (1).docxAccepted version179.12 kBMicrosoft WordView/Open
Title: Circulating microRNAs in small-bowel neuroendocrine tumors: a potential tool for diagnosis and assessment of effectiveness of surgical resection
Authors: Malczewska, A
Frampton, AE
Mato Prado, M
Ameri, S
Dabrowska, AF
Zagorac, S
Clift, AK
Kos-Kudła, B
Faiz, O
Stebbing, J
Castellano, L
Frilling, A
Item Type: Journal Article
Abstract: OBJECTIVE: To discover serum-based microRNA (miRNA) biomarkers for small-bowel neuroendocrine tumors (SBNET) to help guide clinical decisions. BACKGROUND: MiRNAs are small noncoding RNA molecules implicated in the initiation and progression of many cancers. MiRNAs are remarkably stable in bodily fluids, and can potentially be translated into clinically useful biomarkers. Novel biomarkers are needed in SBNET to determine disease aggressiveness, select patients for treatment, detect early recurrence, and monitor response. METHODS: This study was performed in 3 stages (discovery, validation, and a prospective, longitudinal assessment). Discovery comprised of global profiling of 376 miRNA in sera from SBNET patients (n = 11) versus healthy controls (HCs; n = 3). Up-regulated miRNAs were subsequently validated in additional SBNET (n = 33) and HC sera (n = 14); and then longitudinally after SBNET resection (n = 12), with serial serum sampling (preoperatively day 0; postoperatively at 1 week, 1 month, and 12 months). RESULTS: Four serum miRNAs (miR-125b-5p, -362-5p, -425-5p and -500a-5p) were significantly up-regulated in SBNET (P < 0.05; fold-change >2) based on multiple normalization strategies, and were validated by RT-qPCR. This combination was able to differentiate SBNET from HC with an area under the curve of 0.951. Longitudinal assessment revealed that miR-125b-5p returned towards HC levels at 1 month postoperatively in patients without disease, whereas remaining up-regulated in those with residual disease (RSD). This was also true at 12 months postoperatively. In addition, miR-362-5p appeared up-regulated at 12 months in RSD and recurrent disease (RCD). CONCLUSIONS: Our study represents the largest global profiling of serum miRNAs in SBNET patients, and the first to evaluate ongoing serum miRNA expression changes after surgical resection. Serum miR-125b-5p and miR-362-5p have potential to be used to detect RSD/RCD.
Issue Date: 1-Jul-2021
Date of Acceptance: 1-Aug-2019
URI: http://hdl.handle.net/10044/1/72516
DOI: 10.1097/SLA.0000000000003502
ISSN: 0003-4932
Publisher: Lippincott, Williams & Wilkins
Start Page: e1
End Page: e9
Journal / Book Title: Annals of Surgery
Volume: 274
Issue: 1
Copyright Statement: © 2019 Wolters Kluwer Health, Inc. All rights reserved. This document is the Accepted Manuscript version of a published work that appeared in final form in Annals of Surgery, 1 August 2019, https://doi.org/10.1097/SLA.0000000000003502
Sponsor/Funder: Dr. Heinz-Horst Deichmann Stiftung
Cancer Research UK
National Institute for Health Research
Imperial College Healthcare NHS Trust- BRC Funding
Funder's Grant Number: n/a
RDB01 79560
Keywords: Surgery
11 Medical and Health Sciences
Publication Status: Published
Conference Place: United States
Online Publication Date: 2019-08-01
Appears in Collections:Department of Surgery and Cancer
Faculty of Medicine